TY - JOUR
KW - 3R
KW - AI tools
KW - alternatives to animal testing
KW - lab automation
KW - Tissue engineering
AU - Lukas Königer
AU - Christoph Malkmus
AU - Dalia Mahdy
AU - Thomas Däullary
AU - Susanna Götz
AU - Thomas Schwarz
AU - Marius Gensler
AU - Niklas Pallmann
AU - Danjouma Cheufou
AU - Andreas Rosenwald
AU - Marc Möllmann
AU - Dieter Groneberg
AU - Christina Popp
AU - Florian Groeber-Becker
AU - Maria Steinke
AU - Jan Hansmann
AB - The Food and Drug Administration's recent decision to eliminate mandatory animal testing for drug approval marks a significant shift to alternative methods. Similarly, the European Parliament is advocating for a faster transition, reflecting public preference for animal-free research practices. In vitro tissue models are increasingly recognized as valuable tools for regulatory assessments before clinical trials, in line with the 3R principles (Replace, Reduce, Refine). Despite their potential, barriers such as the need for standardization, availability, and cost hinder their widespread adoption. To address these challenges, the Robotic Enabled Biological Automation (ReBiA) system is developed. This system uses a dual-arm robot capable of standardizing laboratory processes within a closed automated environment, translating manual processes into automated ones. This reduces the need for process-specific developments, making in vitro tissue models more consistent and cost-effective. ReBiA's performance is demonstrated through producing human reconstructed epidermis, human airway epithelial models, and human intestinal organoids. Analyses confirm that these models match the morphology and protein expression of manually prepared and native tissues, with similar cell viability. These successes highlight ReBiA's potential to lower barriers to broader adoption of in vitro tissue models, supporting a shift toward more ethical and advanced research methods.
BT - Advanced Science
DA - 2024
DO - 10.1002/advs.202406608
IS - 45
LA - en
N2 - The Food and Drug Administration's recent decision to eliminate mandatory animal testing for drug approval marks a significant shift to alternative methods. Similarly, the European Parliament is advocating for a faster transition, reflecting public preference for animal-free research practices. In vitro tissue models are increasingly recognized as valuable tools for regulatory assessments before clinical trials, in line with the 3R principles (Replace, Reduce, Refine). Despite their potential, barriers such as the need for standardization, availability, and cost hinder their widespread adoption. To address these challenges, the Robotic Enabled Biological Automation (ReBiA) system is developed. This system uses a dual-arm robot capable of standardizing laboratory processes within a closed automated environment, translating manual processes into automated ones. This reduces the need for process-specific developments, making in vitro tissue models more consistent and cost-effective. ReBiA's performance is demonstrated through producing human reconstructed epidermis, human airway epithelial models, and human intestinal organoids. Analyses confirm that these models match the morphology and protein expression of manually prepared and native tissues, with similar cell viability. These successes highlight ReBiA's potential to lower barriers to broader adoption of in vitro tissue models, supporting a shift toward more ethical and advanced research methods.
PY - 2024
EP - 2406608
ST - ReBiA—Robotic Enabled Biological Automation
T2 - Advanced Science
TI - ReBiA—Robotic Enabled Biological Automation: 3D Epithelial Tissue Production
UR - https://onlinelibrary.wiley.com/doi/abs/10.1002/advs.202406608
VL - 11
Y2 - 2025-10-07
SN - 2198-3844
ER -